

Company Registration No. 3591021 (England and Wales)

BR PHARMA INTERNATIONAL LIMITED
ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 30 JUNE 2003



A04	*AU17HQBK*	0598
COMPANIES HOUSE		13/11/03
COMPANIES HOUSE		14/10/03

BR PHARMA INTERNATIONAL LIMITED

CONTENTS

	Page
Director's report	1 - 2
Auditors' report	3
Abbreviated profit and loss account	4
Abbreviated balance sheet	5
Cash flow statement	6
Notes to the cash flow statement	7
Notes to the abbreviated accounts	8 - 13

BR PHARMA INTERNATIONAL LIMITED

DIRECTOR'S REPORT FOR THE YEAR ENDED 30 JUNE 2003

The director presents his report and financial statements for the year ended 30 June 2003.

Principal activities and review of the business

The principal activity of the company continued to be that of the wholesale of pharmaceutical products.

The director is satisfied with the results for the year under review and looks forward to continued growth in the foreseeable future.

Results and dividends

The results for the year are set out on page 4.

Introduction of Euro Currency

The company has finalised its assessment of the risks and uncertainties associated with the introduction of the Euro currency. Based on this, the director considers the impact will not be material in the context of the company and no significant course of action will be required or material costs incurred.

Director

The following director has held office since 1 July 2002:

B Rabin Esq

Director's interests

The director's interest in the shares of the company was as stated below:

	Ordinary Shares of £ 1 each	
	30 June 2003	1 July 2002
B Rabin Esq	100	100

Auditors

In accordance with section 385 of the Companies Act 1985, a resolution proposing that Newman & Partners be reappointed as auditors of the company will be put to the Annual General Meeting.

BR PHARMA INTERNATIONAL LIMITED

DIRECTOR'S REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2003

Director's responsibilities

Company law requires the director to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable him to ensure that the financial statements comply with the Companies Act 1985. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the board



Mrs R M Rabin

Secretary

06 OCT 2003

BR PHARMA INTERNATIONAL LIMITED

INDEPENDENT AUDITORS' REPORT TO BR PHARMA INTERNATIONAL LIMITED UNDER SECTION 247B OF THE COMPANIES ACT 1985

We have examined the abbreviated accounts set out on pages 4 to 13, together with the financial statements of the company for the year ended 30 June 2003 prepared under section 226 of the Companies Act 1985.

Respective responsibilities of the director and auditors

The director is responsible for preparing the abbreviated accounts in accordance with section 246A of the Companies Act 1985. It is our responsibility to form an independent opinion as to whether the company is entitled to deliver abbreviated accounts prepared in accordance with section 246A(3) of the Act to the Registrar of Companies and whether the accounts to be delivered are properly prepared in accordance with that provision and to report our opinion to you.

Basis of audit opinion

We have carried out the procedures we considered necessary to confirm, by reference to the financial statements, that the company is entitled to deliver abbreviated accounts and that the abbreviated accounts to be delivered are properly prepared. The scope of our work for the purpose of this report did not include examining or dealing with events after the date of our report on the financial statements.

Opinion

In our opinion the company is entitled to deliver abbreviated accounts prepared in accordance with section 246A(3) of the Companies Act 1985, and the abbreviated accounts on pages 4 to 13 are properly prepared in accordance with that provision.



07 OCT 2003

Newman & Partners

Chartered Accountants
Registered Auditor

.....
Lynwood House
373/375 Station Road
Harrow, Middlesex
HA1 2AW

BR PHARMA INTERNATIONAL LIMITED

ABBREVIATED PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 30 JUNE 2003

	Notes	2003 £	2002 £
Gross profit		3,456,628	2,081,987
Distribution costs		(8,544)	(24,568)
Administrative expenses		(395,106)	(1,766,705)
Operating profit	2	3,052,978	290,714
Other interest receivable and similar income		22,530	2,650
Interest payable and similar charges	3	(221)	(614)
Profit on ordinary activities before taxation		3,075,287	292,750
Tax on profit on ordinary activities	4	(934,236)	(85,246)
Profit on ordinary activities after taxation		2,141,051	207,504
Dividends	5	(1,466,666)	-
Retained profit for the year	12	674,385	207,504


BR PHARMA INTERNATIONAL LIMITED

ABBREVIATED BALANCE SHEET AS AT 30 JUNE 2003

	Notes	2003 £	£	2002 £	£
Fixed assets					
Tangible assets	6		68,415		80,990
Current assets					
Stocks	7	688,126		1,078,444	
Debtors	8	2,104,481		1,904,502	
Cash at bank and in hand		2,406,472		846,033	
		<u>5,199,079</u>		<u>3,828,979</u>	
Creditors: amounts falling due within one year	9	<u>(3,991,734)</u>		<u>(3,312,997)</u>	
Net current assets			<u>1,207,345</u>		<u>515,982</u>
Total assets less current liabilities			<u>1,275,760</u>		<u>596,972</u>
Provisions for liabilities and charges	10		<u>(12,469)</u>		<u>(8,066)</u>
			<u>1,263,291</u>		<u>588,906</u>
Capital and reserves					
Called up share capital	11		100		100
Profit and loss account	12		<u>1,263,191</u>		<u>588,806</u>
Shareholders' funds - equity interests	13		<u>1,263,291</u>		<u>588,906</u>

These abbreviated accounts have been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to medium-sized companies.

The financial statements were approved by the Board on 06 OCT 2003


B. Rabin Esq
Director

06 OCT 2003

BR PHARMA INTERNATIONAL LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED 30 JUNE 2003

	2003		2002	
	£	£	£	£
Net cash inflow from operating activities		1,637,561		644,630
Returns on investments and servicing of finance				
Interest received	22,530		2,650	
Interest paid	(221)		(614)	
	<u> </u>		<u> </u>	
Net cash inflow for returns on investments and servicing of finance		22,309		2,036
Taxation		(83,023)		(69,030)
Capital expenditure				
Payments to acquire tangible assets	(1,198)		(71,121)	
	<u> </u>		<u> </u>	
Net cash outflow for capital expenditure		(1,198)		(71,121)
		<u> </u>		<u> </u>
Net cash inflow before management of liquid resources and financing		1,575,649		506,515
Management of liquid resources				
Bank deposits	(1,808,262)		-	
	<u> </u>		<u> </u>	
		(1,808,262)		-
		<u> </u>		<u> </u>
(Decrease)/increase in cash in the year		<u><u>(232,613)</u></u>		<u><u>506,515</u></u>

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 30 JUNE 2003

1	Reconciliation of operating profit to net cash inflow from operating activities	2003	2002
		£	£
	Operating profit	3,052,978	290,714
	Depreciation of tangible assets	13,773	16,445
	Decrease/(increase) in stocks	390,318	(495,001)
	Increase in debtors	(199,979)	(1,110,160)
	(Decrease)/Increase in creditors within one year	(1,619,529)	1,942,632
	Net cash inflow from operating activities	1,637,561	644,630

2	Analysis of net funds	1 July 2002	Cash flow	Other non-cash changes	30 June 2003
		£	£	£	£
	Net cash:				
	Cash at bank and in hand	846,033	(247,823)	-	598,210
	Bank overdrafts	(15,210)	15,210	-	-
		<u>830,823</u>	<u>(232,613)</u>	<u>-</u>	<u>598,210</u>
	Liquid resources:				
	Bank deposits	-	1,808,262	-	1,808,262
	Net funds	830,823	1,575,649	-	2,406,472

3	Reconciliation of net cash flow to movement in net funds	2003	2002
		£	£
	(Decrease)/increase in cash in the year	(232,613)	506,515
	Cash outflow from increase in liquid resources	1,808,262	-
	Movement in net funds in the year	1,575,649	506,515
	Opening net funds	830,823	324,308
	Closing net funds	2,406,472	830,823

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 30 JUNE 2003

1 Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention.

1.2 Compliance with accounting standards

The financial statements are prepared in accordance with applicable accounting standards.

1.3 Turnover

Turnover represents amounts receivable for goods and services net of VAT and trade discounts.

1.4 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Computer equipment	33.33% reducing balance method
Fixtures, fittings and equipment	15% reducing balance method

1.5 Leasing

Rentals payable under operating leases are charged against income on a straight line basis over the lease term.

1.6 Stock

Stock is valued at the lower of cost and net realisable value.

1.7 Deferred taxation

Deferred tax is provided in full in respect of taxation deferred by timing differences between the treatment of certain items for taxation and accounting purposes. The deferred tax balance has not been discounted.

1.8 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.

2 Operating profit

	2003	2002
	£	£
Operating profit is stated after charging:		
Depreciation of tangible assets	13,773	16,445
Operating lease rentals	30,000	24,440
Auditors' remuneration	14,000	13,790
and after crediting:		
Profit on foreign exchange transactions	(78,208)	(403)

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2003

3	Interest payable	2003	2002
		£	£
	On bank loans and overdrafts	221	614
		<u> </u>	<u> </u>
4	Taxation	2003	2002
		£	£
	Domestic current year tax		
	U.K. corporation tax	924,061	77,250
	Adjustment for prior years	5,772	(70)
		<u> </u>	<u> </u>
	Current tax charge	929,833	77,180
	Deferred tax		
	Origination and reversal of timing differences	4,403	8,066
		<u> </u>	<u> </u>
		934,236	85,246
		<u> </u>	<u> </u>
	Factors affecting the tax charge for the year		
	Profit on ordinary activities before taxation	3,075,287	292,750
		<u> </u>	<u> </u>
	Profit on ordinary activities before taxation multiplied by standard rate of UK corporation tax of 30.00 % (2002 : 30.85 %)	922,586	90,313
		<u> </u>	<u> </u>
	Effects of:		
	Non deductible expenses	100	-
	Depreciation add back	4,132	5,073
	Capital allowances	(2,757)	(10,070)
	Adjustments to previous periods	5,772	(70)
	Other tax adjustments	-	(8,066)
		<u> </u>	<u> </u>
		7,247	(13,133)
		<u> </u>	<u> </u>
	Current tax charge	929,833	77,180
		<u> </u>	<u> </u>
5	Dividends	2003	2002
		£	£
	Final dividend proposed on ordinary shares	1,466,666	-
		<u> </u>	<u> </u>

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2003

6 Tangible fixed assets

	Computer equipment	Fixtures, fittings and equipment	Total
	£	£	£
Cost			
At 1 July 2002	11,893	93,616	105,509
Additions	1,198	-	1,198
At 30 June 2003	13,091	93,616	106,707
Depreciation			
At 1 July 2002	5,230	19,289	24,519
Charge for the year	2,620	11,153	13,773
At 30 June 2003	7,850	30,442	38,292
Net book value			
At 30 June 2003	5,241	63,174	68,415
At 30 June 2002	6,663	74,327	80,990

7 Stocks

	2003	2002
	£	£
Goods for resale	688,126	1,078,444

8 Debtors

	2003	2002
	£	£
Trade debtors	2,000,539	1,806,111
Other debtors	95,703	85,183
Prepayments and accrued income	8,239	13,208
	2,104,481	1,904,502

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2003

9 Creditors: amounts falling due within one year	2003 £	2002 £
Bank loans and overdrafts	-	15,210
Trade creditors	358,333	893,429
Corporation tax	924,060	77,250
Other taxes and social security costs	403,761	1,461,067
Director's current accounts	499,524	772,847
Other creditors	441	866
Accruals and deferred income	338,949	92,328
Proposed dividend	1,466,666	-
	<u>3,991,734</u>	<u>3,312,997</u>

10 Provisions for liabilities and charges

	Deferred tax liability £
Balance at 1 July 2002	8,066
Profit and loss account	4,403
	<u>12,469</u>
Balance at 30 June 2003	<u>12,469</u>

The deferred tax liability is made up as follows:

	2003 £	2002 £
Accelerated capital allowances	<u>12,469</u>	<u>8,066</u>

11 Share capital

	2003 £	2002 £
Authorised		
100 Ordinary Shares of £ 1 each	<u>100</u>	<u>100</u>
Allotted, called up and fully paid		
100 Ordinary Shares of £ 1 each	<u>100</u>	<u>100</u>

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2003

12 Statement of movements on profit and loss account

	Profit and loss account £
Balance at 1 July 2002	588,806
Retained profit for the year	674,385
Balance at 30 June 2003	<u>1,263,191</u>

13 Reconciliation of movements in shareholders' funds

	2003 £	2002 £
Profit for the financial year	2,141,051	207,504
Dividends	(1,466,666)	-
Net addition to shareholders' funds	<u>674,385</u>	<u>207,504</u>
Opening shareholders' funds	588,906	381,402
Closing shareholders' funds	<u>1,263,291</u>	<u>588,906</u>

14 Financial commitments

At 30 June 2003 the company had annual commitments under non-cancellable operating leases as follows:

	Land and buildings 2003 £	2002 £
Expiry date: Between two and five years	<u>30,000</u>	<u>30,000</u>

15 Director's emoluments

	2003 £	2002 £
Emoluments for qualifying services	<u>32,000</u>	<u>1,281,108</u>

BR PHARMA INTERNATIONAL LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2003

16 Employees

Number of employees

The average monthly number of employees (including directors) during the year was:

	2003 Number	2002 Number
Administration	16	7

Employment costs

	£	£
Wages and salaries	285,043	1,423,938
Social security costs	25,591	164,214
	310,634	1,588,152